© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
January 08, 2021
If approved, the treatment would be the first SGLT2 inhibitor for patients with chronic kidney disease.
Atopic Dermatitis Severity Linked to Incremental Societal Healthcare Costs
Strong Response Maintenance for Plaque Psoriasis Patients Using Tildrakizumab
Clinical Efficacy, Safety of Brolucizumab Similar to Trial Results for nAMD Patients